- Lung cancer is by far the leading cause of cancer death among both men and women, making up more than 25% of cancer deaths.1
- Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 85% of cases.1
- Despite recent advances in the treatment of advanced lung cancer, there remains a high unmet need for patients and outcomes remain poor.2
- Approximately 50% of NSCLC patients have an oncogene, that initiates cancer and contributes to its growth.3
- KRAS G12C, a newly actionable biomarker, occurs in 13%, or 1 in 8 NSCLC patients in the U.S.4
- Comprehensive biomarker testing at diagnosis is critical because it can help patients develop a targeted and personalized treatment plan.5,6
- Depending on stage at diagnosis and a patient’s biomarker status, NSCLC treatment options may include chemotherapy, immunotherapy, radiation, surgery, or targeted therapies.7
- For patients with a mutational driver identified by biomarker testing, treatment with targeted therapy is associated with improved outcomes for patients.6*
- ACS. About Lung Cancer – Key Statistics. Available at: https://www.cancer.org/cancer/lung-cancer/about/key-statistics.html. Accessed 4/25/2021.
- ACS. Early Detection, Diagnosis, and Staging – Lung Cancer Survival Rates. Available at: https://www.cancer.org/cancer/lung-cancer/detection-diagnosis-staging/survival-rates.html. Accessed 4/25/2021.
- Baumgart M. Am J Hematol Oncol. 2015;11:10-13.
- Amgen Data on File: Analysis of AACR Genie v8, 7-A-Table.
- Barlesi F, et al. Lancet. 2016;387:1415-1426.
- Kris MG, et al. JAMA. 2014;311: 1998-2006.
6* Median overall survival (mOS) of 3.5 months in patients receiving targeted therapy enabled by biomarker testing compared to 2.4 months mOS in patients with a driver mutation not receiving targeted therapy. - ACS. Treating Non-Small Cell Lung Cancer. Available at: https://www.cancer.org/cancer/lung-cancer/treating-non-small-cell.html. Accessed 4/25/21.
